Daratumumab Not Cost-Effective for Multiple Myeloma
Researchers sought to determine whether adding daratumumab to standard care for patients with multiple myeloma was a cost-effective option.
Multiple Myeloma
Ixazomib in an Oral Triplet Therapy Shows Benefit for Newly Diagnosed Multiple Myeloma
Researchers sought to determine whether adding ixazomib to treatment with lenalidomide plus dexamethasone would give a benefit to patients with newly diagnosed multiple myeloma.
Abecma Approved for Relapsed/Refractory Multiple Myeloma
Abecma is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy.
Can Premedications, Infusion Rates Be Adjusted Safely With Daratumumab for Multiple Myeloma?
A retrospective analysis sought to determine the effect of omitting premedications and use of a rapid infusion rate on infusion-related reactions in patients receiving daratumumab for multiple myeloma.
SIRT1 Inhibitor Cambinol Has Antitumor Activity in Multiple Myeloma Cells
Researchers sought to determine whether cambinol would have antitumor activity in multiple myeloma cells.
Pharmacy-Based VTE Screening Mitigated Risk in Myeloma Patients
A team of investigators sought to improve the rates of anticoagulation for high-risk patients after a quality improvement project that added pharmacy/hematology oversight to VTE risk assessment.
Pepaxto Approved for Triple-Class Refractory Multiple Myeloma
The approval was based on data from the multicenter, single-arm phase 2 HORIZON trial.
Selinexor Triplet Therapy Provides Survival Benefit for Multiple Myeloma
Researchers sought to determine if selinexor, bortezomib, and dexamethasone would give better responses over doublet therapy for patients with multiple myeloma.
CAR-T Cell Therapy Promising in Multiple Myeloma
Researchers sought to determine whether idecabtagene vicleucel, a CAR-T cell therapy, would be a viable treatment option in heavily pretreated patients with relapsed or refractory multiple myeloma.
MagnetisMM-3 Trial to Test BCMA-CD3 Bispecific Antibody in Relapsed/Refractory Multiple Myeloma
The phase 2 MagnetisMM-3 trial will test the safety and efficacy of subcutaneous elranatamab (PF-06863135) for relapsed or refractory multiple myeloma.
-
Loading...
-
Loading...
Next post in Myeloma
